This document discusses two studies on analyzing DNA variations to predict disease outcomes and develop new treatments. The first study found that a new biomarker called cMethDNA detected in blood samples could predict the survival of women with advanced breast cancer within 4 weeks of treatment. The second study identified DNA variations associated with inflammatory cytokines and found an existing drug may treat multiple sclerosis and Crohn's disease. Both studies demonstrated how analyzing genetic variations could help customize treatment approaches for patients.